The abstract is read at the publisher; the summary is JClub's.
In 2022 claims for 12,134 Medicare and commercially insured patients with blood-cancer SOAM prescriptions, only 9.6% (Medicare) and 4.0% (commercial) were approved and filled initially.
- Why it matters: Even when specialty oral anticancer drugs are indicated for blood cancers, payer denials and patient affordability may prevent patients from starting therapy.
- What they did: The study used nationwide claims to track new SOAM prescriptions in 2022, classifying outcomes as rejected, approved-not-filled, or approved-and-filled at presentation and within 90 days, and analyzing rejection reasons and fill rates by out-of-pocket cost.
- The result: Within 90 days, approval rose to 85.0% (Medicare) and 62.8% (commercial), yet only 54.5% (Medicare) and 45.5% (commercial) both received approval and filled; fill rates fell sharply when OOP exceeded $175 USD.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.